Senate Finance Hearing on Drug Pricing — The Senate Finance Committee held a hearing this week on drug pricing, and Senators questioned seven CEOs from top pharmaceutical companies. While Senators of both parties asked tough questions about pricing practices and price increases, some experts suggested that the hearing was tamer than expected. In the Washington Post, Paige Cunningham wrote, “In the hearing on drug prices [...]

Patient True Talk is the only patient-to-patient registry where patients and/or their caregivers can create profiles with as much information as they feel comfortable sharing, and find matching profiles based on algorithms created by some of the country’s top clinical oncologists. Patients/caregivers can also search along their diagnosis/treatment parameters, refining their search based on the results provided. They can then send secure messages [...]

Drug Pricing at SOTU; House Health Care Hearing — At the State of the Union address, President Trump stated that two of his administration’s health care priorities are to protect individuals with pre-existing conditions and lower drug prices. The address did not specify how to achieve those goals. NCCS commented on several drug pricing proposals released previously by the administration, with a specific focus on what the proposals would mean for patients. [...]

The Department of Health and Human Services (HHS) released recently a proposed rule to change Medicare Part D’s protected classes drug coverage. In response, NCCS joined with other patient and provider groups of the Cancer Leadership Council (CLC) to comment on how these proposed changes could impact patients. The proposed rule would give Medicare plans the option to limit coverage of drugs in six categories, including cancer drugs. [...]